Sunday, October 20, 2019, 14:09

The narcolepsy drug, developed by Irish company Jazz Pharmaceuticals, has a lower salt content than the current treatment Xyrem, making it more suitable for patients at risk of cardiovascular disease. 

In a 200-patient phase III trial that finished in July, Jazz Pharmaceutical’s experimental drug was able to reduce the number of cataplexy attacks and the sleepiness of narcolepsy patients as compared to a placebo.

To continue reading this article click here

No comments yet.
(*) Required fields
Copyright ©2019 Narcolepsy, No One Gets It ! , All Rights Reserved. 
Website hosted by
News stats: 20191716